Literature DB >> 15379946

Signet ring cell adenocarcinoma of the urachus.

Singh Daljeet1, Singh Amreek, Jain Satish, Arora Raman, G S Hara, Garg Lovneesh, B R Prabhakar, Aggarwal Neeraj.   

Abstract

Signet ring cell adenocarcinoma of the urachus is an extremely rare variety of adenocarcinoma of the urachus; only 23 cases have been reported in the literature to date. In the present report we discuss two more cases of this type and review the literature. For our first case, a 17-year-old man was treated with partial cystectomy with en-bloc excision of the urachus and umbilicus. He received local radiotherapy because of positive surgical margins. Local recurrence occurred after 21 months of diagnosis and he was lost to follow up. For our second case, a 31-year-old man was found to have peritoneal carcinomatosis at the time of surgery and partial cystectomy was carried out as a palliative procedure for hematuria. He received six cycles of chemotherapy, a combination of methotrexate, vinblastine, adriamycin and cisplatinum. The patient's response to the chemotherapy lasted for 8 months, after which his disease progressed and he died 19 months after diagnosis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15379946     DOI: 10.1111/j.1442-2042.2004.00892.x

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  3 in total

1.  Signet Ring Cell Carcinoma of Urachal Origin Presenting as Irritative Lower Urinary Tract Symptoms and Pain Abdomen: A Rare Case Report.

Authors:  Amit Verma; Vinay Tomar
Journal:  J Clin Diagn Res       Date:  2016-07-01

2.  Investigation and management of suspected urachal anomalies in children.

Authors:  B R Yapo; B Gerges; A J A Holland
Journal:  Pediatr Surg Int       Date:  2008-03-21       Impact factor: 1.827

Review 3.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.